Abstract
Purpose The aim of this study is to report the short-term efficacy of aflibercept in the treatment of neovascular age-related macular degeneration (AMD) with associated retinal pigment epithelial detachment (PED) which is refractory or develops tachyphylaxis to bevacizumab and ranibizumab.
Methods The method comprised a retrospective review of the medical records of patients with neovascular AMD and associated PEDs recently treated with aflibercept and previously treated with bevacizumab and ranibizumab.
Results Three eyes of three female patients of ages 49, 55, and 65 years old with large serous PEDs and subretinal fluid (SRF) associated with occult choroidal neovascularization and neovascular AMD were treated with aflibercept after intravitreal bevacizumab and/or ranibizumab failed to resolve the lesions. All had complete resolution of SRF and complete or nearcomplete resolution of the PEDs after aflibercept injections over a 3-month period.
Visual acuity improved in all three eyes. Conclusion Intravitreal aflibercept may be an effective treatment option for serous PED in neovascular AMD patients after bevacizumab and ranibizumab have previously failed. Larger studies with longer follow-up are required to determine the role of aflibercept in treatment of PED in neovascular AMD.
Introduction
Retinal pigment epithelial detachments (PEDs) occur in up to 62% of eyes with advanced age-related macular degeneration (AMD). 1 Numerous treatment options have been employed for PEDs in AMD, including laser therapies and intravitreal injections of vascular endothelial growth factor (VEGF) antibodies. 2 However, eyes with PEDs were excluded from the larger clinical trials that used macular laser, 3 photodynamic therapy, 4 or ranibizumab 5, 6 to treat neovascular AMD; therefore, the efficacy of such options is still unclear for eyes with choroidal neovascularization (CNV) and PEDs. Aflibercept is a recombinant fusion protein, which binds all isomers of the VEGF-A family and placental growth factor. It has higher binding affinity for VEGF and was shown to be clinically equivalent to ranibizumab, in two large studies, in treating neovascular AMD. 7 We report three cases with large PEDs associated with neovascular AMD successfully treated with aflibercept after failed treatment with bevacizumab and ranibizumab.
Case reports

Case 1
A 49-year-old Caucasian female with a history of bilateral neovascular AMD treated with bevacizumab Â 1 OD and Â 2 OS, elsewhere presented with a large serous PED OD and multiple small PEDs OS. Bestcorrected visual acuities (BCVAs) were 20/60 OD and 20/25 OS. The PED OD resolved after three ranibizumab injections. However, the left eye developed a single, large PED with subretinal fluid (SRF). Fluorescein angiogram (FA) and indocyanine green confirmed neovascular AMD with occult CNV and multiple macular and peripheral drusen. The PED OS worsened with increased SRF despite eight ranibizumab injections over 9 months, including a trial of two increased doses (1.0 mg) of ranibizumab. BCVA OS dropped to 20/70. After one intravitreal injection of aflibercept, the SRF resolved with nearly complete resolution of the PED. Two additional injections of aflibercept were given and the foveal contour normalized. BCVA OS 3 months after the initial aflibercept injection was 20/25 ( Figure 1 ).
Case 2
A 55-year-old Caucasian female with neovascular AMD OD status post five monthly ranibizumab intravitreal injections presented with a large PED associated with CNV. FA confirmed occult CNV OD. Initial BCVAs were 20/25 OD and 20/20 OS. The PED OD initially improved with two bevacizumab and one ranibizumab intravitreal injections over a 7-month period, but the PED later worsened despite three increased doses of ranibizumab injections (1.5 mg) over a 2-month period. BCVA decreased to 20/30 OD. One aflibercept injection was then given, resulting in a near-complete resolution of the PED. This was followed by two monthly aflibercept 
Discussion
PEDs have a significant impact on vision with no proven treatment options. An average vision loss of more than three lines over 1 year was seen in about 50% of patients with a newly diagnosed PED. 8 Polypoidal vascular choroidopathy (PCV) is also known to cause large PEDs and are less responsive to ranibizumab and bevacizumab monotherapy. 9 Although PCV is possible, the demographics of cases 1 and 2 and the presence of multiple drusen in all three cases make AMD a more likely diagnosis.
Cases 1 and 2 possibly represent tachyphylaxis, whereas case 3 more likely represents failure to bevacizumab and/or ranibizumab. Tachyphylaxis is the reduced efficacy of a drug when used repeatedly over a short period of time, with no response occurring when the dosage is increased. 10 The incidence of tachyphylaxis to anti-VEGF in AMD ranged from 2% in ranibizumab 11 to 8.5% in bevacizumab. 12 It has been shown that in AMD patients who developed tachyphylaxis to ranibizumab or bevacizumab, 81% demonstrated some response after switching therapies. 13 Although aflibercept may be effective, the dramatic response was not universal in all patients. Six other patients with large PEDs secondary to neovascular AMD, who failed other treatment, were treated with aflibercept at our institution. Six of these patients had unchanged PED size after switching to aflibercept-three had complete resolution of SRF associated with their PED, two had fluctuation of SRF, and one never developed SRF at 3-month follow-up. Visual acuity improved in one patient, remained stable in four patients, and worsened in one patient. Although response varies, the dramatic, short-term resolution of the PEDs in the three recalcitrant cases suggests that aflibercept may be useful in the treatment of large PEDs associated with occult CNV. However, larger randomized controlled studies are necessary to determine its role in the treatment of PED in neovascular AMD.
Summary
What was known before K Serous retinal PEDs are complications often seen in neovascular AMD.
K Previous treatment for PEDs with anti-VEGF therapy, such as bevacizumab and ranibizumab, has had inconsistent results.
K Aflibercept is a new form of anti-VEGF therapy with a higher binding affinity for VEGF-A and additional binding to placental growth factor.
What this study adds
K Treatment with aflibercept resulted in near-immediate resolution of serous PEDs, which were previously unresponsive to multiple injections of bevacizumab and ranibizumab in three eyes of three patients.
K Aflibercept may be an effective form of treatment for serous PEDs in neovascular AMD.
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